Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Jun 6;30(7):1913–1922. doi: 10.1038/s41591-024-03044-0

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2024

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Extended Data Fig. 6 — a, Progression-free survival (PFS) for targeted monotherapy (mono) and targeted dual therapy. b, Evaluable response and objective clinical benefit (OCB) rate by type of targeted therapy. c, PFS and OS by types of treatment. d, Evaluable response and OCB by cancer types. e, PFS and OS by cancer types. Two-sided log rank test is used to compare the Kaplan Meier survival curves of 2 groups, with the reference subgroup indicated by a dash and P value next to the group for comparison. Two-sided chi-square test is used to compare evaluable response and OCB rate between 2 groups and the P values are presented in Table 1. CR, complete response; DMG, diffuse midline glioma H3K27M-altered; HGG, high grade glioma; HM, hematologic malignancy; PR, partial response; PD, progressive disease; SD, stable disease.